In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. Diabetes Assays are tests to first diagnose diabetes and assess the risk of diabetes, such as pre-diabetes, through analysis of blood. GlobalData uses proprietary data and analytics to provide a comprehensive report on the diabetes assays devices market, including market shares of different players within Sweden. Buy the latest report here.
In 2022, GlobalData’s Market Model methodology determined that the leading player in the diabetes assays market in Sweden was Abbott Laboratories followed by Siemens, F. Hoffmann-La Roche, Danaher, Bio-Rad Laboratories, EKF Diagnostics, Quidelortho, Sinocare, DiaSorin and Tosoh.
The Diabetes Assays market comprises C-Peptide Assay, Glycated Hemoglobin (HbAc) Lab Assay, Glycated Hemoglobin (HbAc) Point of care (POC) Assay, Insulin Assay, and Fasting Glucose Assay
Following the widespread disruption resulting from the COVID-19 pandemic to the broader medical devices market during 2020 and 2021, the value of the diabetes assays devices market within Sweden was expected to be over $3m in 2022.
For the latest complete market share analysis of diabetes assays device market in Sweden, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.